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Abstract
Rationale It has recently been found that chronic treatment
with the highly selective, brain-penetrating Y5 receptor antag-
onist, Lu AA33810 [N-[[trans-4-[(4,5-dihydro [1]
benzothiepino[5,4-d] thiazol-2-yl) amino] cyclohexyl]methyl]-
methanesulfonamide], produces antidepressant-like effects in
the rat chronic mild stress model.
Objective In the present study, we investigated the possible
antidepressant-like activity of Lu AA33810 in rats subjected to
glial ablation in the prefrontal cortex (PFC) by the gliotoxin L-
AAA, which is an astroglial degeneration model of depression.
ResultsWe observed that Lu AA33810 administered intraper-
itoneally at a single dose of 10 mg/kg both reversed
depressive-like behavioral changes in the forced swim test
(FST) and prevented degeneration of astrocytes in the
mPFC. The mechanism of antidepressant and glioprotective
effects of Lu AA33810 has not been studied, so far. We dem-
onstrated the contribution of the noradrenergic rather than the
serotonergic pathway to the antidepressant-like action of Lu
AA33810 in the FST. Moreover, we found that
antidepressant-like effect of Lu AA33810 was connected with
the influence on brain-derived neurotrophic factor (BDNF)
protein expression. We also demonstrated the antidepressant-
like effect of Lu AA33810 in the FST in rats which did not
receive the gliotoxin. We found that intracerebroventricular
injection of the selective MAPK/ERK inhibitor U0126
(5 μg/2 μl) and the selective PI3K inhibitor LY294002
(10 nmol/2 μl) significantly inhibited the anti-immobility ef-
fect of Lu AA33810 in the FST in rats, suggesting that
MAPK/ERK and PI3K signaling pathways could be involved
in the antidepressant-like effect of Lu AA33810.
Conclusion Our results indicate that Lu AA33810 exerts an
antidepressant-like effect and suggest the Y5 receptors as a
promising target for antidepressant therapy.
Keywords Astrocyte . Antidepressant . BDNF . Lu
AA33810 . GFAP . Neuropeptide Y . Prefrontal cortex .
Gliotoxin . Forced swim test
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Major depressive disorder (MDD), also called major depres-
sion, is the commonly occurring mental disease affecting more
than 120 million people worldwide (Belmaker and Agam
2008). Despite intensive research in the last 60 years, currently
used antidepressant therapies are not efficient enough and de-
pression requires long-term treatment (Thompson et al. 2015).
Approximately 30% of patients with depression fail to respond
to currently available therapies, which mainly influence mono-
aminergic systems, therefore, research aimed to find new drugs
is still in progress (Prins et al. 2011). The difficulties in efficient
antidepressant treatment may be caused by a heterogeneous
nature of this mood disorder, associated with different molecu-
lar, environmental, and genetic factors. In the last years, studies
on depression have shifted from monoamines toward other
mechanisms, including glutamatergic neurotransmission
(Catena-Dell’Osso et al. 2013).
Glutamate, the major excitatory neurotransmitter in the
mammalian brain, is in a balance with gamma-aminobutyric
acid (GABA), which is the main inhibitory amino acid neuro-
transmitter in the brain (Cotman et al. 1981; Lloyd et al. 1986;
Wierońska and Pilc 2009). It can be suggested that dysregula-
tion of Glu/GABA is involved in the pathogenesis of depres-
sion (Wierońska and Pilc 2009; Hashimoto 2009). An in-
creased level of Glu was found in the brains and cerebrospinal
fluid (CSF) of depressed patients (Hashimoto et al. 2007) as
well as in their serum (Kim et al. 1982) and plasma (Altamura
et al. 1993; Mitani et al. 2006). Furthermore, several studies
have shown that the inhibition of glutamatergic neurotransmis-
sion was strongly correlated with the therapeutic action of a
majority of antidepressant drugs (Paul and Skolnick 2003).
Glial cells, especially astrocytes, play a crucial role in the
maintenance of Glu/GABA balance (Anderson and Swanson
2000; Schousboe 2003;Wierońska and Pilc 2009). These cells
are a critical structural and functional part of the tripartite
synapses, in which they play a direct and interactive role with
neurons in synaptic transmission (Araque et al. 1999; Halassa
et al. 2007). A number of evidences have shown that the
dysfunction of astrocytes may be involved in the pathogenesis
of depression. Postmortem studies performed on brains of
depressed patients demonstrated that a decrease in the density
of glial cells in cortical regions, especially in the prefrontal and
cingular areas (Ongür et al. 1998; Rajkowska et al. 1999;
Rajkowska 2000; Rajkowska et al. 2001; Cotter et al. 2001,
2002; Gittins and Harrison 2011) and in the hippocampus
(Cobb et al. 2016) was one of the most consistent findings.
These decreases were associated with a reduced level of as-
trocytic markers, such as glial fibrillary acidic protein (GFAP)
(Miguel-Hidalgo et al. 2000) and glutamine synthetase
(Choudary et al. 2005). It is interesting that a reduction in
the number of astrocytes in the prefrontal cortex (PFC) was
also found in rats exposed to chronic unpredictable stress,
which is an animal model of depression (Banasr and Duman
2008; Banasr et al. 2010). Those authors showed that astro-
cytic degeneration in the PFC provoked by gliotoxin L-alpha-
aminoadipic acid (L-AAA) induced depressive-like behavior
just like chronic stress (Banasr and Duman 2008), which sup-
ports the hypothesis that ablation of glia cells may contribute
to development of depression (Banasr et al. 2010). This hy-
pothesis was also confirmed by our previous study, in which
microinjection of L-AAA into the rat PFC produced
depressive-like behavior observed in the forced swim test
(FST), and this effect was reversed by the classical antidepres-
sant imipramine and mGluR5 antagonist 3-[(methyl-1,3-
thiazol-4-yl)ethynyl]-pyridine (MTEP), a compound with an-
xiolytic and antidepressant-like properties (Domin et al.
2014). Moreover, biochemical and immunohistochemical
studies showed that MTEP also prevented the astrocytic de-
generation in this model of depression (Domin et al. 2014).
It was postulated that neuropeptides, especially NPY,might
play a significant role in the pathophysiology of depression
(Morales-Medina et al. 2010; Morales-Medina et al. 2012a;
Kormos and Gaszner 2013). NPY is a 36-amino acid peptide
that is widely distributed in the mammalian central nervous
system (CNS) (Chronwall et al. 1985; Gray and Morley
1986). In the forebrain, NPY is present on GABAergic inter-
neurons, where it is involved in the inhibition of the release of
other neurotransmitters, e.g., glutamate (Greber et al. 1994;
Silva et al. 2005). As a neurotransmitter and neuromodulator,
NPY activates the specific membrane bound G-protein-
coupled receptors (GPCRs) denoted as Y1, Y2, Y3, Y4, Y5,
and Y6 (Michel et al. 1998). All these receptor subtypes me-
diate the NPY’s biological responses via the Gαi signaling
pathway (Michel 1991; Dumont et al. 1992). There are a
number of data indicating that NPY and its receptor ligands
produced antidepressant-like effects in animal models of de-
pression (Stogner and Holmes 2000; Redrobe et al. 2002;
Ishida et al. 2007; Walker et al. 2009; Packiarajan et al.
2011; Morales-Medina et al. 2012b; Desai et al. 2014).
Furthermore, significant changes in NPY-like immunoreactiv-
ity (NPY-ir) were observed not only in animal models of de-
pressive disorders (Jiménez-Vasquez et al., 2000a,2000b; Wu
et al. 2011) but also in depressed patients who presented re-
duced levels of NPY in the cerebrospinal fluid and plasma in
several studies (Widerlöv et al. 1988; Westrin et al. 1999;
Heilig et al. 2004; Soleimani et al. 2014). The above-
mentioned results showed that among the NPY receptors,
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the Y1, Y2, and Y5 receptors (YR) were involved in
depression-related disorders. Moreover, the role of Y4R in
depression has also been postulated (Painsipp et al. 2008;
Tasan et al. 2009). However, despite the promising results
indicating that Y receptors may be hopeful targets for antide-
pressant therapy, the potential therapeutic use of the YR mod-
ulators, agonists and antagonists, has not been clinically vali-
dated yet.
Recently, it has been found that a highly selective and po-
tent Y5R antagonist, [N-[[trans-4-[(4,5-dihydro[1]
benzothiepino [5,4-d]thiazol-2-yl) amino] cyclohexyl] meth-
yl]-methanesulfonamide] Lu AA33810, produced
antidepressant-like effects in the rat chronic mild stress model
and anxiolytic-like effects in the social interaction test (Walker
et al. 2009; Packiarajan et al. 2011). This compound could
easily cross the blood-brain barrier and was effective after oral
and peripheral administration which may be important from
the point of view of its possible future clinical applications. To
further investigate the role of Y5 receptors in depression-
related disorders, in the present study, we examined a possible
antidepressant-like activity of Lu AA33810 in rats subjected
to glial ablation in the PFC by the gliotoxin L-AAA, as a
useful astroglial degeneration model of depression. We tried
to find out whether this Y5R antagonist may counteract the
effects of astrocyte ablation on behavioral, biochemical, and
immunohistochemical parameters. Since no studies identified
the signaling pathways engaged in the antidepressant-like ef-
fect of Lu AA33810, in the present study, we investigated
whether its antidepressant-like effect is connected with an in-
fluence on brain-derived neurotrophic factor (BDNF) protein
expression, as its role in the therapeutic effect of antidepres-
sants has been postulated (Schmidt et al. 2008; Autry and
Monteggia 2012). Moreover, a growing body of data suggests
that mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) and phosphatidylinositol 3-
kinase (PI3K) signaling pathways are implicated in the path-
ophysiology of depression and in the antidepressant-like effect
of different compounds (Zeni et al. 2012; Di Benedetto et al.
2013), therefore, we examined an involvement of these path-




The experiments were performed on male Spraque-Dawley
rats (Charles River, Germany) weighing about 250–300 g.
The animals were maintained under standard laboratory con-
ditions of lighting (light phase: 7:00–19:00) and temperature
(19–21 °C). The rats were age-matched and were housed five
to a cage with free access to water and food. All manipulations
were performed between 8:00–14.00. All procedures were
conducted according to the guidelines of the National
Institutes of Health Animal Care andUse Committee and were
approved by the Ethics Committee of the Institute of
Pharmacology, Polish Academy of Sciences in Krakow.
Every effort was made to minimize animal suffering and to
reduce the number of animals used.
Cannulae implantation
For experiments involving a central administration of com-
pounds, rats were anesthetized with ketamine (75 mg/kg
i.m.) and xylazine (10 mg/kg i.m.) and, stereotaxically, bilat-
erally implanted with guide cannulae aimed at the medial pre-
frontal cortex (mPFC) region (AP = +3.2 mm, L = +1.0 mm
from the Bregma, H = −3.5 mm from the skull) or into the
brain ventricles (AP = −0.4 mm, L = +1.5 mm from the
Bregma, H = −4.6 mm from the skull) (Paxinos and Watson
1986). The guide cannulae (23-gauge stainless steel tubing),
were secured by dental cement and anchored to the skull by
two stainless steel screws. In order to prevent clogging, stain-
less steel stylets were placed in the guide cannulae and left
until the animals were microinjected. Seven days later, the rats
were subjected to behavioral testing and the injections of the
drugs into the brain were made with Hamilton micro syringes
connected via polyethylene tubing to two stainless steel
needles. Solutions were administered bilaterally for 60 s.
The injection needles were kept in place for an additional
60 s before they were removed and replaced with a stylet.
Drug administration
The following drugs were used: L-alpha-aminoadipic acid (L-
AAA) (Sigma-Aldrich Chemie GmbH, Germany); [N-[[trans-
4-[(4,5-dihydro[1] benzothiepino [5,4-d]thiazol-2-yl) amino]
cyclohexyl] methyl]-methanesulfonamide] Lu AA33810; 1,4-
diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene
(U0126)—n inhibi tor of MAPK/ERK; and 2-(4-
morpho l i no ) -8 -pheny l -4H-1 -benzopy ran -4 -one
(LY294002)—an inhibitor of PI3K (Tocris Bioscience, UK).
In order to evoke gliotoxic effect, on the 1st and 2nd day of the
experiment, the rats were bilaterally microinjected into the
mPFC with the astrocytic toxin L-AAA. L-AAAwas freshly
dissolved in 0.1 M phosphate buffer, pH 7.4, and was
microinjected at the dose of 100 μg/2 μl. Control rats were
bilaterally injectedwith a vehicle according to the same sched-
ule. Afterwards, depressive-like behavior was assessed by the
FST 72 h (on day 5) after the second gliotoxin or vehicle
administration. The dose of L-AAA and the schedule of treat-
ment were chosen on the basis of our previous study (Domin
et al. 2014). In order to assess antidepressant-like activity of
the Y5R antagonist, the rats were treated with Lu AA33810 in
a single dose of 10 mg/kg, 60 min before the FST. Lu
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AA33810 was dispersed in 0.5% methylcellulose and was
administered intraperitoneally (i.p.) in a volume of 1 ml/kg.
Control rats received vehicle according to the same schedule.
In the next part of the study, to examine the involvement of
MAPK/ERK and PI3-K signaling pathways in the
antidepressant-like effect of Lu AA33810, we used the inhib-
itors of these intracellular pathways, U0126 and LY294002,
respectively. U0126 (5μg/2μl) and LY294002 (10 nmol/2 μl)
were dissolved in 0.1 M phosphate buffer, pH 7.4, and were
administered by the intracerebroventricular (i.c.v.) route (1 μl/
site) 15 min before Lu AA33810 (10 mg/kg) in rats which did
not receive the gliotoxin. Test FSTwas performed 1 h after the
single administration of Lu AA33810. The doses of the used
drugs were selected on the basis of literature data for in vivo
treatments (for Lu AA33810 from Walker et al. (2009) and
Packiarajan et al. (2011); for U0126 and LY294002 from Zeni
et al. (2012) and Manosso et al. (2015)). The same protocol of
the administration of the above-mentioned drugs was used to
evaluate their influence on the locomotor activity.
Forced swim test
Procedure of the test was described in the paper by Szewczyk
et al. (2009). Briefly, the rats were placed in glass cylinders
(height 40 cm, diameter 20 cm) containing 15 cm of water,
maintained at 25 °C. Generally, FST consists of two swim
sessions: an initial 15-min pretest followed 24 h later by a 5-
min test. After both sessions, rats were removed from cylin-
ders, dried, and returned to their home cages. During the 5-
min test session, three different behaviors were scored accord-
ing to Detke et al. (1995): (1) immobility—rats remained
floating passively in the water, (2) swimming—rats weremak-
ing active swimming motions, and (3) climbing—rats were
making active movements in and out of the water with their
forepaws, directed against the walls.
Locomotor activity
Following the FST, the locomotor activity of rats was mea-
sured. Rats were placed individually in Opto-Varimex cages
(Columbus Instruments, USA) connected on-line to a compat-
ible IBM-PC. The behavior of the rats was analyzed using an
auto-track software (Columbus Instruments, USA). Each cage
(43 × 44 × 25 cm) had a 15 × 15 array of infrared emitter
photocell beams located 3 cm from the floor surface. The
number of light beams interrupted by an animal was calculat-
ed at 5-min intervals and presented as the distance traveled in
centimeters.
Western blot analysis
On the eighth day (144 h after the second gliotoxin injection),
the rats were decapitated and their brains were collected. The
PFC was rapidly taken by cutting the anterior part of the fore-
brain at the level of bregma 2.20 mm (Paxinos and Watson
1986). The tissue were frozen on dry ice and stored at −80 °C
until biochemical experiments. This step started from tissue
homogenization that was conducted in a 2% solution of sodi-
um dodecyl sulfate (SDS). The homogenates were then dena-
tured at 95 °C for 10 min and centrifuged for 5 min at
10,000 rpm at 4 °C, and the supernatant was collected. The
protein concentration was determined using a Pierce BCA
Protein Assay Kit (Thermo Scientific, USA). Next, 30 μg of
protein were separated by 10% SDS-polyacrylamide gel elec-
trophoresis and transferred to nitrocellulose membranes
(Invitrogen, Paisley, UK). Non-specific binding was blocked
for 1 h in 1% blocking solution [BM Chemiluminescence
Western Blotting Kit (Mouse/Rabbit), Roche, Switzerland].
After blocking, the membranes were incubated overnight at
4 °C with the respective primary antibodies: mouse monoclo-
nal anti-GFAP antibody (1:1000, Millipore, Germany), mouse
monoclonal anti-GAD67 antibody (1:1000, Millipore,
Germany), rabbit polyclonal anti-BDNF antibody (1:500,
Santa Cruz Biotechnology, USA), rabbit polyclonal anti-
NPYantibody (1:500, Sigma-Aldrich, USA), rabbit polyclon-
al anti-NPY5R antibody (1:1000, Abcam, USA), and rabbit
polyclonal anti-TrkB antibody (1:1000, Abcam, USA). After
incubation, the membranes were washed three times for
10 min in Tris-buffered saline with Tween (TBS-T) and incu-
bated for 30 min with anti-mouse/ant-rabbit-IgG-peroxidase-
conjugated antibodies (BM Chemiluminescence Western
Blotting Kit, mouse/rabbit, Roche; diluted 1:7000)). After in-
cubation with secondary antibodies, the membranes were
washed three times for 10 min with TBS-T. In the last step,
the blots were incubated with a detection reagent (Roche). The
signal from the tested proteins was visualized using the Fuji-
Las 1000 system. The density of each protein band was quan-
tified using the Fuji Image Gauge v.4.0 software. To confirm
the equal transfer and loading of the samples on the gel, the
blots were incubated with rabbit polyclonal anti-GAPDH an-
tibody (1:1000, Bios). The final results are presented as the
ratio of the optical density of particular proteins to the optical
density of GAPDH.
Histology and immunohistochemistry
On the eighth day of the experiment, the brains were collected
for histological and immunohistochemical analysis, as de-
scribed previously (Domin et al. 2014). Briefly, the rats deeply
anesthetized by pentobarbital were perfused through the as-
cending aorta with physiological saline, followed by a cold
4% paraformaldehyde (PF) in 0.1 M sodium phosphate buffer
(PBS), pH 7.4. Then, their brains were taken out, postfixed in
cold buffered PF for 3 h, and cryoprotected in a 20% sucrose
solution in PBS for at least 5 days at 4 °C. Next, the brains
were frozen on dry ice and cut at 40 μm frontal sections, at
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levels containing mPFC (between bregma 4.70 to 1.70 mm)
(Paxinos and Watson 1986). Sections were collected in PBS
and every sixth section was taken for immunohistochemistry.
First, the sections were permeabilized with 0.1 M PBS con-
taining 0.2% Triton X-100 (PBS-TX-100) for 30 min after
which the blocking was performed in the presence of 5%
normal horse serum (NHS) or 5% normal goat serum (NGS)
in PBS at room temperature (RT) for 30 min. Next, the sec-
tions were incubated (48 h at 4 °C) with the following primary
antibodies: mouse monoclonal anti-GFAP antibody (1:800,
Millipore, Germany) and rabbit polyclonal anti-BDNF anti-
body (1:100, Santa Cruz Biotechnology, USA). Anti-GFAP
antibody was diluted in 0.2% PBS-TX-100 and 3% NHS and
anti-BDNF antibodies was diluted in 0.2% PBS-TX-100 and
3% NGS. After that time, the sections were washed in PBS
and incubated for 60 min at RT in the secondary antibodies:
anti-mouse IgG (1:500) or anti-rabbit IgG (1:500). Next, the
sections were processed by an avidine-biotin peroxidase com-
plex method using an ABC-peroxidase kit (Vector Lab) and
diaminobenzidine (DAB) as a chromogen. Additionally, in
order to verify the injection sites, the sections adjacent to those
labeled with the GFAP or BDNF antibodies were stained with
1% cresyl violet. In the last step, the immunostained sections
were washed in Tris and were mounted on slides, dried,
dehydrated, cleared in xylene, cover-slipped with Permount,
and analyzed under a light microscope Nikon Eclipse E600
(Nikon, Japan).
Immunofluorescence staining
In order to visualize Y5R- and GAD67-immunoreactive (ir)
neurons, the sections were blocked with 0.01 M PBS contain-
ing 0.2% Triton X-100 and 5% normal donkey serum at RT
for 1 h. After that time, the sections were incubated (48 h at
4 °C) with the following primary antibodies: goat polyclonal
anti-NPY Y5R antibody (1:50, Santa Cruz Biotechnology,
USA) and mouse monoclonal anti-GAD67 antibody
(1:1000, Millipore, Germany) diluted in the blocking buffer.
Next, the sections were washed in PBS and incubated over-
night at 4 °C in the followingmixture of secondary antibodies:
Alexa Fluor® 488-labeled donkey anti-goat IgG and Alexa
Fluor® 555-labeled donkey anti-mouse IgG (Invitrogen,
Poland) diluted in 0.2% PBS-TX-100 and 3% normal donkey
serum. After that time, sections were washed in PBS and
mounted with a coverslip overlay. For double labeling, the
slices were analyzed with a fluorescent microscope Nikon
Eclipse E600 (Nikon, Japan), which was equipped with
black-white camera (Leica Microsystems CMS, GmbH
Germany) connected to a computer equipped with Leica
Application Suite (LAS) version 4.5 software at excitation
wavelengths of 465–495 nm (Alexa Fluor® 488) and 540–
580 nm (Alexa Fluor® 555).
Stereological counting of GFAP-ir cells within the mPFC
GFAP-ir cells in the mPFC were counted stereologically
using a light microscope (Leica, DMLB; Leica,
Denmark) equipped with a projecting camera (Basler
Vision Technologies, Germany) and a microscope stage
connected to an xyz stepper (PRIOR ProScan) con-
trolled by a computer using Visiopharm New CAST
software (Visiopharm, Denmark) as described previously
(Domin et al. 2014).
Systemic uniform, random sampling was used to select
the sections for the analysis. For stereological assessment,
cell counts were performed within the contours of the
mPFC (AP = 4.70 to 1.70 mm from bregma) (Paxinos
and Watson 1986) in 10–12 sections at 240-μm intervals.
The analyzed region was outlined under lower magnifica-
tion (×5), while the number of GFAP-positive cells was
estimated under ×63 magnification using a randomized
meander sampling and the optical dissector methods ac-
cording to the formula: N = ΣQ × V (ref)/v (dis) × ΣP,
where ΣQ is a total count of GFAP-ir astrocytes in the
uniformly sampled dissectors, V (ref)—the total volume
of the mPFC, v (dis)—the total volume of the dissector
(Sterio 1984), and ΣP—the total number of all dissector
points. The total volume of the mPFC V (ref) was
assessed using the Cavalieri’s rule (Gundersen et al.
1999) according to the formula: V (ref) = t × a
(p) × ΣP, where t is the known distance between the
sampled sections, a (p) is the area associated with each
point of a grid, and ΣP is the total number of counted
points over all sections from one rat. The area of counting
frame was 5559.37 μm2 and covered 20% of the screen
area. The dissector height was 20 μm and a sampling grid
was 333.45 × 333.45 μm (111,188.9 μm2). The efficacy
of sampling was optimized by the estimation of the coef-
ficient of error (CE) as previously described (West et al.
1996).
Counting of BDNF-ir cells within the mPFC
The number of BDNF-ir cells in the rat mPFC was quantified
within four stained sections from each brain (AP = 4.20 to
2.20 mm from bregma) (Paxinos and Watson 1986) using a
light microscope (Leica, DMLB; Leica, Denmark). Only dis-
tinct brown cells clearly visible above a background were
considered to be immunopositive. The analyzed area was
outlined under lower magnification (×5), while the number
of BDNF-positive cells was counted under ×63 magnification
using a randomized meander sampling and the optical dissec-
tor methods using the Visiopharm New CAST software
(Visiopharm, Denmark). The area of counting frame was
5455.76 μm2. The dissector height was 20 μm and a sampling
grid was 330.33 × 330.33 μm (109,117,9 μm2).
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Statistical analysis
All results are presented as the means ± SEM.Behavioral data,
immunoblots, and immunohistochemical analysis were eval-
uated using the two-way ANOVA (analysis of variance),
followed by the Newman-Keuls (behavioral results) or
Bonferroni (biochemical and immunohistochemical results)
multiple comparison post hoc tests (GraphPad Software, San
Diego CA, USA). The differences were considered to be sta-
tistically significant at p < 0.05.
Results
Behavioral studies
The effect of combined administration of L-AAA and Lu
AA33810 in the FST in rats
To investigate the possible antidepressant-like activity of Lu
AA33810 in rats subjected to glial ablation, we examined the
effect of L-AAA and LuAA33810 in the FST. Comparedwith
the control group, the immobility time increased significantly
in L-AAA-treated rats (100 μg/2 μl) (p < 0.05, Fig. 1a), indi-
cating that L-AAA-induced, depressive-like behavioral
changes in the FST in rats. L-AAA decreased also the
climbing time; however, this effect was not significant
(Fig. 1b). L-AAA had no influence on the swimming time
of rats (Fig. 1c). Lu AA33810 (10 mg/kg) given alone signif-
icantly decreased the immobility time (p < 0.05) and signifi-
cantly increased the climbing time (p < 0.05) but had no effect
on swimming time of rats when compared to the control group
(Fig. 1). Compared with the L-AAA-treated group, Lu
AA33810 reversed L-AAA-induced increase in the immobil-
ity time (p < 0.01) and climbing time (p < 0.01) but had no
effect on the swimming time (Fig. 1). Results of two-way
ANOVA for immobility: [F(1,40) = 5.50, p = 0.0240] for L-
AAA; [F(1,40) = 18.91, p = 0.0001] for Lu AA33810 and
[F(1,40) = 0.17, p = 0.6820] for L-AAA and Lu AA33810
interaction; for climbing: [F(1,40) = 4.91, p = 0.0324] for L-
AAA; [F(1,40) = 20.34, p = 0.0001] for Lu AA33810 and
[F(1,40) = 0.003, p = 0.9521] for L-AAA and Lu AA33810
interaction; for swimming: [F(1,40) = 0.25, p = 0.6189] for L-
AAA; [F(1,40) = 0.37, p = 0.5471] for Lu AA33810 and
[F(1,40) = 3.30, p = 0.0769] for L-AAA and Lu AA33810
interaction.
The influence of the inhibitors of MAPK/ERK and PI3K
signaling pathways on the antidepressant-like effect of Lu
AA33810 in the FST in rats
Since previous studies suggested the involvement of
MAPK/ERK and PI3K signaling pathways in the
antidepressant-like effect of different compounds (Zeni et al.
2012; Di Benedetto et al. 2013), we examined the effect of
U0126 (an MAPK/ERK inhibitor) and LY294002 (a PI3K
inhibitor) pretreatment on the antidepressant-like effect of
Lu AA33810 in the FST in rats. As shown in Fig. 2a, pretreat-
ment with U0126 (5 μg/2 μl) blocked the anti-immobility
effect of Lu AA33810 (p < 0.05) but did not influence the
behavior of rats when given alone (p > 0.05). Two-way
ANOVA showed a significant effect of Lu AA33810 [F (1,
23) = 6.74 p = 0.0161], no effect of U0126 [F(1,23) = 1.45,
p = 0.2407], and insignificant interaction [F(1,23) = 3.53
p = 0.0728]. As shown in Fig. 2b, LY294002 (10 nmol/2 μl)
given alone 75 min before the test did not influence the be-
havior of rats (p > 0.05) but significantly blocked the
antidepressant-like effect of Lu AA33810 (p < 0.05). Two-
way ANOVA showed a significant effect of Lu AA33810 [F
(1,26) = 7.12 p = 0.0130], a significant effect of LY294002
[F(1,26) = 5.41, p = 0.0281] and insignificant interaction
[F(1,26) = 1.35 p = 0.2560].
Fig. 1 The effect of L-AAA and Lu AA33810 administered alone or in
combination on the immobility (a), climbing (b), and swimming time (c)
in the FST in rats. L-AAAwas administered twice into the rat mPFC at a
dose of 100 μg/2 μl, on the first and second day of the experiment and the
FST was performed 72 h after the second toxin injection. Lu AA33810,
10 mg/kg, i.p., was given 60 min before the FST. The obtained data were
presented as the means ± SEM (n = 6–14 rats per group) and evaluated by
two-way ANOVA followed by the Newman-Keuls multiple comparison
test. *p < 0.05 vs. control; ##p < 0.01 vs. L-AAA-treated group
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The effect of L-AAA, Lu AA33810, and the inhibitors
of MAPK/ERK and PI3K signaling pathways
on the locomotor activity of rats
L-AAA and Lu AA33810 administered alone or in combined
treatment did not significantly change the locomotor activity
of rats (Table 1a). No significant changes in the locomotor
activity of rats were also observed after administration of Lu
AA33810, U0126, LY294002, or the combination of these
compounds (Table 1b). Two-way ANOVA demonstrated: for
Table 1a: [F(1,33) = 8.45, p = 0.006] for LAAA;
[F(1,33) = 0.003, p = 0.956] for Lu AA33810; and
[F(1,33) = 0.93, p = 0.341] for L-AAA and Lu AA33810
interaction and for Table 1b: [F(2,29) = 0.674, p = 0.517] for
U0126 and LY294002 inhibitors; [F(1,29) = 0.199, p = 0.658]
for Lu AA33810; and [F(2,29) = 0.401, p = 0.672] for Lu
AA33810 and inhibitors interaction.
Western blot analysis
The effect of combined administration of L-AAA and Lu
AA33810 on the GFAP protein level in the rat PFC
Since previous studies showed a correlation between astrocyt-
ic degeneration in the mPFC and depression-like behavioral
changes (Banasr and Duman 2008; Domin et al. 2014), we
examined the effects of L-AAA and Lu AA33810 on the
GFAP protein level in the rat PFC. L-AAA administration
induced a significant reduction in the GFAP protein level in
the rat PFC (p < 0.05) (Fig. 3a). Lu AA33810 alone had no
effect on the GFAP protein level; however, it antagonized the
effect induced by L-AAA (p < 0.01) (Fig. 3a). Two-way
ANOVA demonstrated no effect of L-AAA [F(1,31) = 1,19
p = 0.2835], a significant effect of Lu AA33810
[F(1,31) = 5.06, p = 0.0317], and a significant interaction
[F(1.31) = 5.09, p = 0.0313].
Fig. 2 The effects of MAPK/ERK and PI3K inhibitors on the
antidepressant-like effect of Lu AA33810 in the FST in rats.
Pretreatment with U0126 (5 μg/2 μl/rat, i.c.v.), an MAPK/ERK
inhibitor (a) and LY294002 (10 nmol/2 μl/rat, i.c.v.) a PI3K inhibitor
(b) 75 min before the test prevented the anti-immobility effect of Lu
AA33810 treatment (10 mg/kg, i.p., 60 min before the test) in the FST
in rats. The obtained data were presented as the means ± SEM (n = 6–9
rats per group) and evaluated by two-way ANOVA, followed by the
Newman-Keuls multiple comparison test. *p < 0.05 vs. control;
#p < 0.05 vs. Lu AA33810 treated group
Table 1 The effect of L-AAA and Lu AA33810 administered alone or
in combined treatment (A) and the effect of combined treatment of Lu
AA33810 with the inhibitors of MAPK/ERK and PI3K signaling path-
ways (B) on the locomotor activity of rats
Treatment Activity counts (5-min test)
A
Control 100.0 ± 8.61
L-AAA 118.4 ± 9.79
Lu AA33810 90.34 ± 7.04
L-AAA + Lu AA33810 127.0 ± 12.85
B
Control 100.0 ± 29.9
Lu AA33810 142.4 ± 44.3
U0126 150.3 ± 48.88
Lu AA33810+U0126 121.0 ± 28.75
LY294002 69.36 ± 14.48
Lu AA33810+LY294002 103.1 ± 64.26
The time schedule for the effect of L-AAA, Lu AA33810, and inhibitors
is adequate to that used in the FST. The doses of the used compounds are
L-AAA (twice at a dose of 100 μg/2 μl), Lu AA33810 (10 mg/kg, i.p.),
U0126 (5μg/2 μl/rat, i.c.v.), and LY294002 (10 nmol/2 μl/rat, i.c.v.). The
values represent the mean ± SEM (n = 8–16 rats per group) and were
evaluated by two-way ANOVA, followed by the Bonferroni multiple
comparison test
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The effect of combined administration of L-AAA and Lu
AA33810 on the BDNF and TrkB protein levels in the rat PFC
To determine whether BDNF/TrkB signaling pathway is in-
volved in the antidepressant-like effect of Lu AA33810, we
examined the effects of L-AAA and Lu AA33810 on the
BDNF and TrkB proteins levels in the rat PFC. L-AAA ad-
ministration induced a significant reduction in the BDNF pro-
tein level in the rat PFC (p < 0.05) (Fig. 3b). Lu AA33810
alone had no effect on BDNF protein level; however, it antag-
onized the effect induced by L-AAA (p < 0.05) (Fig. 3b).
Two-way ANOVA demonstrated a significant effect of L-
AAA [F(1,27) = 4.28 p = 0.0482], no effect of Lu AA33810
[F(1,27) = 2.08, p = 0.1608], and a significant interaction
[F(1.27) = 4.52, p = 0.0408]. L-AAA administration induced
a significant reduction in the TrkB protein level in the rat PFC
(p < 0.05) (Fig. 3c). Lu AA33810 alone had no effect on TrkB
protein level and did not antagonize the effect induced by L-
AAA (p > 0.05) (Fig. 3c). Two-way ANOVA demonstrated a
significant effect of L-AAA [F (1,23) = 8.22 p = 0.0087], no
effect of Lu AA33810 [F(1,23) = 0.08, p = 0.7824], and a
significant interaction [F (1.23) = 3.17, p = 0.0884].
The effect of combined administration of L-AAA and Lu
AA33810 on the Y5 receptor protein level in the rat PFC
To determine whether Y5 receptors are implicated in the
gliotoxin model of depression, we examined the effect of L-
AAA and Lu AA 33810 on the Y5R protein level in the rat
PFC. L-AAA administration induced a significant increase in
the Y5R protein level in the rat PFC (p < 0.05) (Fig. 3d). Lu
AA33810 alone had no effect on Y5R protein level and did
not antagonize the effect induced by L-AAA (p > 0.05)
(Fig. 3d). Two-way ANOVA demonstrated a significant effect
of L-AAA [F(1,34) = 6.74 p = 0.0138], no effect of Lu
AA33810 [F(1,34) = 3,97, p = 0.0545], and a non-
significant interaction [F(1,34) = 0.78, p = 0.3847].
Fig. 3 The effect of L-AAA (100 μg/2 μl, twice) and Lu AA33810
(10 mg/kg, i.p.) administered alone or in combination on the protein level
of GFAP (a), BDNF (b), TrkB (c), and Y5 receptor (Y5R) (d) in the rat
PFC determined by Western blot analysis 144 h after the second toxin
injection. Data are expressed as% changes vs. control. Immunoblot bands
corresponding to GFAP, BDNF, TrkB, Y5R, and GAPDH are seen (e).
Values represent the mean ± SEM (n = 6–10 rats per group) and were
evaluated by two-way ANOVA, followed by the Bonferroni multiple
comparison test. *p < 0.05, **p < 0.01 vs. control; #p < 0.05,
##p < 0.01 vs. L-AAA-treated group
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Histological and immunohistochemical analysis
The effect of combined administration of L-AAA and Lu
AA33810 on the number of GFAP-positive cells in the rat
mPFC
Microscopic observation of sections stained with cresyl violet
showed correct cannula placement in the mPFC (data not
shown). A reduction of density of GFAP-ir astrocytes was
observed in the mPFC of rats injected with L-AAA (Fig. 4,
upper panel). Stereological counting demonstrated a signifi-
cant decrease (by ca. 50%) in the number of GFAP-positive
cells in the mPFC after L-AAA compared with control rats
(p < 0.001) (Fig. 4, bottom panel). Like in Western blot anal-
ysis, Lu AA33810 had no effect on the number of GFAP-ir
cells, however, it antagonized the effect induced by L-AAA
(p < 0.05) (Fig. 4, bottom panel). Two-way ANOVA demon-
strated no effect of L-AAA [F (1.31) = 1.19 p = 0.2835], a
significant effect of Lu AA33810 [F(1,31) = 5.06,
p = 0.0317], and a significant interaction [F(1,31) = 5.09,
p = 0.0313]. The glioprotective effect of Lu AA33810, which
was assessed by stereological counting, was confirmed by the
microscopic observation of GFAP-positive cells in the mPFC
(Fig. 4, upper panel).
The effect of combined administration of L-AAA and Lu
AA33810 on the number of BDNF-ir cells in the rat mPFC
Like the Western blot results, immunohistochemical analysis
also showed the decrease in BDNF-ir in the mPFC of rats
injected with L-AAA in comparison to control rats, whereas
treatment with Lu AA33810 reversed this effect (Fig. 5, upper
panel). Compared with the control group, BDNF-ir cells in the
mPFC of the L-AAA-treated group decreased to 47%
(p < 0.05; Fig. 5, bottom panel). Lu AA33810 alone did not
evoke any changes in the number of BDNF-ir cells. However,
compared with the L-AAA-treated group, there was a signif-
icant increase in the number of BDNF-ir cells in the mPFC of
Fig. 4 (Upper panel)
Representative microphotographs
of coronal sections of the rat
brain, illustrating the effect of L-
AAA (100 μg/2 μl, twice) and Lu
AA33810 (10 mg/kg, i.p.)
administered alone or in
combination on the number of
GFAP-positive cells in the mPFC.
Numerous GFAP-positive
astrocytes are seen in the section
from a control rat in contrast to
few astrocytes in the section from
L-AAA injected rat. Moreover,
the shrinkage of astrocyte cells
and processes is also seen after the
gliotoxin. LuAA33810 prevented
the decrease in the number of
astrocytes and their pathological
changes. Calibration bars 50 μm.
(Bottom panel) A histogram
showing the number of GFAP-
positive cells counted by
stereological method. Data are
expressed as % changes vs.
control. Values represent the
mean ± SEM (n = 5–6 rats per
group) and were evaluated by
two-way ANOVA, followed by
the Bonferroni multiple
comparison test. ***p < 0.001 vs.
control; #p < 0.05 vs. L-AAA-
treated group
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the L-AAA+Lu AA33810 group, and the value reached the
control value (p < 0.01; Fig. 5, bottom panel).
The results of double immunofluorescence staining
Microscopic examination of mPFC sections immunostained
with anti-NPY Y5R and anti-GAD67 antibodies has shown
that Y5R-ir was often found on GAD67-ir neurons (Fig. 6).
Discussion
The obtained results indicate that the highly selective Y5 re-
ceptor antagonist, Lu AA33810, produced antidepressant-like
effects in the astroglial ablation model of depression in rats.
This compound both reversed depressive-like behavioral
changes induced by gliotoxin and prevented degeneration of
astrocytes in the PFC. Antidepressant-like activity of Lu
Fig. 5 (Upper panel)
Representative microphotographs
of coronal sections of the rat brain
showing the expression of
BDNF-positive cells in the mPFC
of the experimental groups. Many
BDNF-positive cells are seen in
the control rat. Gliotoxin L-AAA
(100 μg/2 μl, twice) induced a
strong decrease in the number of
BDNF-ir cells, while Lu
AA33810 (10 mg/kg, i.p.)
reversed this effect. Arrows point
to some of BDNF-positive cells.
Calibration bars 50 μm. (Bottom
panel) A histogram showing the
effect of L-AAA and Lu
AA33810 administered alone or
in combination on the number of
BDNF-ir cells in the rat PFC.
Data are expressed as % changes
vs. control. Values represent the
mean ± SEM (n = 5–6 rats per
group) and were evaluated by
two-way ANOVA, followed by
the Bonferroni multiple
comparison test. *p < 0.05 vs.
control; ##p < 0.001 vs. L-AAA-
treated group
Fig. 6 Fluorescence microphotographs of sections of the rat brain mPFC
showing immunostaining with anti-NPY Y5R (a) and anti-GAD67 (b)
antibodies. Double-positive neurons are shown bywhite arrows (c).Gray
arrow points to one of GAD67-positive, Y5-negative neuron.Calibration
bars 25 μm
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AA33810 was examined in the FST which is a preclinical
behaviora l tes t wide ly used for examina t ion of
antidepressant-like activity of different drugs (Porsolt et al.
1978; Cryan et al. 2002). A decrease in the immobility time
in the FSTwith no changes in locomotor activity observed by
us in the present study after injection of Lu AA33810 both in
rats subjected to glial ablation and in rats which did not receive
gliotoxin indicates antidepressant potential of this compound.
The original FST measured only the immobility time in ro-
dents (Porsolt et al. 1977) whereas the modified FST also
measures the swimming time, which is sensitive to serotoner-
gic compounds, and climbing time which is sensitive to drugs
with selective effects on noradrenergic transmission (Detke
et al. 1995; Cryan et al. 2005). Therefore, the FST may also
give us a suggestion on an involvement of serotonergic or
noradrenergic pathways in the antidepressant activity of tested
compound, since it was found that acceleration of the seroto-
nergic neurotransmission reduced immobility and enhanced
the swimming time, while the noradrenergic system activation
was associated with a decrease in immobility and improve-
ment of climbing activity (Detke et al. 1995). In the present
study, Lu AA33810 both decreased the immobility time and
enhanced the climbing behavior but did not change the swim-
ming time. Taking together, the above-mentioned our and
others’ results can suggest that the noradrenergic rather than
the serotonergic neurotransmission is involved in the
antidepressant-like action of Lu AA33810 in the FST.
However, further studies are needed to elucidate the involve-
ment of noradrenergic signaling in the antidepressant-like ef-
fect of this compound.
The novelty of our present findings is that antidepressant-
like effect of Lu AA33810 has been found after a single acute
dose (10 mg/kg, i.p.). Other authors studying antidepressant-
like effect of LuAA33810 focused rather on chronic treatment
(Walker et al. 2009; Packiarajan et al. 2011). Antidepressant-
like effect of Lu AA33819 in rats subjected to chronic mild
stress, measured by a normalization of stress-induced decrease
in sucrose consumption, was found in response to 10 mg/
kg i.p. twice a day in the second week of treatment
(Packiarajan et al. 2011) or in response to 3 mg/kg/day i.p.
in the third week (Walker et al. 2009). The discrepancies be-
tween our and other studies could be explained by the fact that
various models of depression (acute glial ablation model of
depression vs. chronic mild stress), different strains of rats
(Spraque-Dawley vs. Wistar), and different tests for evalua-
tion of potential antidepressant-like effect (FST vs. sucrose
consumption test) were used. The studies by Walker et al.
(2009) also showed antidepressant-like effect of Lu
AA33810 (10 mg/kg/day i.p.) in the FST following chronic
treatment, but in contrast to our study, they found such effect
of Y5R antagonist in Flinders Sensitive Line (FSL) rats.
The antidepressant efficacy of the Y5R antagonist, Lu
AA33810 is in line with observations of many authors who
evidenced an important role of NPY in mood disorders (see
Introduction). A reduction of the central NPY level and/or func-
tion was observed in experimental and clinical depression
(Caberlotto et al. 1999; Caberlotto and Hurd 1999), whereas
central administration of NPY or Y1R agonist [Leu31,Pro34]-
PYY produced antidepressant-like effects in rats and mice
(Stogner and Holmes 2000; Redrobe et al. 2002; Ishida et al.
2007; Morales-Medina et al. 2012a; Desai et al. 2014); more-
over, these effects were blocked by Y1R antagonists (Redrobe
et al. 2002; Ishida et al. 2007; Desai et al. 2014). On the other
hand, antidepressant-like activity of antagonists of Y2 and Y5
receptors was also observed (Walker et al. 2009; Packiarajan
et al. 2011; Morales-Medina et al. 2012a, 2012b). It seems to be
paradoxical that similar antidepressant-like effect was observed
following treatment with NPY and agonist of Y1R or antago-
nists of Y2 and Y5 receptors. This could be explain by the fact
that YRs are differentially distributed in various brain struc-
tures, both pre- and postsynaptically, and their activation or
inhibition may engage different signaling pathways which un-
derlies the antidepressant-like effects. It seems likely that
antidepressant-like effect observed after activation of postsyn-
aptic Y1R was associated with an enhancement of NPY func-
tion (Redrobe et al. 2002; Ishida et al. 2007). However, Y2R
and Y5R, which are distributed mainly presynaptically, may
negatively regulate NPY release (Chen et al. 1997; King et al.
1999), and antagonism of Y2R and/orY5R would thus be ex-
pected to increase NPY function in the CNS and may prove to
be useful in treating mood disorders. Walker et al. (2009) indi-
cate the antidepressant potential of the Y5R antagonist and its
ability to restore NPY levels, which could be partially relevant
in FSL rats that not only exhibit a depressed phenotype
(Overstreet et al. 2005) but also display an overall reduction
in limbic NPY expression (Caberlotto et al. 1999; Jiménez-
Vasquez et al. 2000a).
Our present Western blot analysis showed a significant
increase in the Y5R protein level in the PFC after administra-
tion of gliotoxin (Fig. 3d). The increase in the level of Y5R
protein in that astrocyte ablation model may be a compensa-
tory reaction to the postulated decrease in NPY function in
depression. Such compensatory increase in receptor level as a
consequence of diminution in neurotransmitter function is a
generally accepted adaptive response (Kurlan and Shoulson
1982; Pokk et al. 1996). Moreover, Y5R increase may be a
result of tissue damage and glutamatergic over-excitation
which seems to occur in the mPFC after gliotoxin as an in-
crease in Y5R was found by other authors in the hypothala-
mus of rats treated with monosodium glutamate (Stricker-
Krongrad and Beck 2004), in rat limbic structures during kin-
dling (Kopp et al. 1999), and in human cortical dysplasia in
intractable epilepsy (Li et al. 2016). Taken together, the in-
crease in the level of Y5R protein in our astrocyte ablation
model suggests that Y5R may play an important role in this
model of depression and that the blockade of Y5R has been
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hypothesized as an indirect way to increase NPY function and
improve depression-like behavior.
In our present study, we observed that GABA neurons
contained Y5R (Fig. 6), thus this result may suggest that
Y5Rs play a role in the regulation of GABAergic neurons in
the mPFC. As mentioned above, Y5R activation could inhibit
the release of NPY and co-expressed transmitters (Gehlert
et al. 2008; Walker et al. 2009), so blockade of these receptors
may restore NPY level through inhibition of inhibitory GABA
neurons. A possibility of regulation of cortical GABA neurons
by Y5Rs was also found by other authors who identified Y5R
in the rat cerebral cortex located on the soma and proximal
dendrites of GABAergic interneurons (Grove et al. 2000; Bari
et al. 2015). Since the model of astrocyte ablation is based on
the dysregulation of Glu/GABA balance, it could be sug-
gested that the antidepressant-like effect of Lu AA33810
may be a result of an indirect modulatory action via GABA
interneurons which influence Glu/GABA balance.
Our present results have shown that there is a correlation
between the astrocytic degeneration in the mPFC and
depression-like behavioral changes in our gliotoxin model, be-
cause Lu AA33810, given after L-AAA, both prevented astro-
cytic degeneration (Fig. 4) and exhibited antidepressant-like
properties in the FST (Fig. 1). These findings are consistent
with our previous results in which we found that L-AAA
injected into the mPFC strongly reduced the number of
GFAP-positive cells and GFAP protein level in this structure;
moreover, the mGlu5 receptor antagonist MTEP, presenting
antidepressant-like properties in this model, diminished also
the degeneration of astrocytes (Domin et al. 2014). Results of
many other authors have also indicated a direct action of anti-
depressants on astrocytes, modifying their morphology, physi-
ology, and gene expression both in experimental studies and in
depressed patients (Liu et al. 2009; Czéh and Di Benedetto
2013; Li et al. 2013). These authors revealed that different
antidepressant treatments (e.g., administration of fluoxetine,
clozapine, clomipramine, or magnolol) regulated the expression
of GFAP as well as other astroglia proteins, such as aquaporin 4
and connexin 43, in the rat frontal cortex and/or hippocampus.
Interestingly, in our present study, we observed that Lu
AA33810 restored the gliotoxin-induced decrease in GFAP ex-
pression after a single dose, whereas other authors have ob-
served the reversal of the glial atrophy after chronic treatment.
The mechanism of antidepressant and glioprotective effects
of Lu AA33810 has not been studied so far. Since an important
role of BDNF/TrkB signaling pathways in the therapeutic effect
of antidepressants has been suggested (Schmidt et al. 2008;
Autry and Monteggia 2012), we investigated the cortical
BDNF and TrkB protein levels after the acute administration
of Lu AA33810 in rats under glial ablation condition. Our
Western blot analysis has shown a strong decrease in the protein
level of both BDNF and its receptor TrkB in the rat PFC after
gliotoxin injection. The decrease in the BDNF protein level was
significantly reversed by Lu AA33810, which had
antidepressant-like effect in the present gliotoxin model of de-
pression (Fig. 3b). Our Western blot results were confirmed by
immunohistochemical analysis showing a reduction in BDNF-
ir after gliotoxin, whereas treatment with LuAA33810 reversed
this effect (Fig. 5). These results are in line with numerous
clinical findings demonstrating that serum BDNF levels are
reduced in depressed patients and then normalized after antide-
pressant treatment (Brunoni et al. 2008; Dreimüller et al. 2012;
Molendijk et al. 2014; Mikoteit et al. 2014; Duclot and Kabbaj
2015; Polyakova et al. 2015). In human postmortem brains
collected from suicide victims with major depression, a de-
crease in TrkB messenger RNA (mRNA) and BDNF mRNA
levels was found in the prefrontal cortex and hippocampus
(Autry and Monteggia 2012). Therefore, it is postulated that
BDNF plays an essential role in the pathophysiology of depres-
sion. Similar results were obtained not only in depressed pa-
tients but also in experimental studies. Stress and glucocorti-
coids decreased BDNF protein level and chronic treatment with
antidepressants increased BDNF protein and mRNA and TrKB
mRNA levels in the rat hippocampus and cortical structures
(Altar 1999; Dias et al. 2003; Altar et al. 2003; Larsen et al.
2008). The efficacy of antidepressants was significantly dimin-
ished or abolished when BDNF/TrkB signaling pathway was
disturbed (Saarelainen et al. 2003; Duclot and Kabbaj 2015). In
the present study, we found that Lu AA33810 both revealed
antidepressant-like effects and counteracted the astroglial de-
generation as well as prevented the decrease in BDNF protein
level, suggesting the involvement of the BDNF signaling path-
way in its antidepressant-like effect in the present gliotoxin
model of depression.
In the present study, we also observed antidepressant-like
effect of Lu AA33810 in the FST in rats which did not receive
gliotoxin. Considering the possible mechanism underlying its
antidepressant-like effect, it should be noted that some authors
suggested that MAPK/ERK and PI3K signaling pathways
could be involved in the therapeutic effect of different com-
pounds (Zeni et al. 2012; Di Benedetto et al. 2013; Manosso
et al. 2015). Our study demonstrated that i.c.v. injection of the
selective MAPK/ERK inhibitor U0126 and the selective PI3K
inhibitor LY294002 significantly inhibited the anti-immobility
effect of Lu AA33810 in the FST in rats (Fig. 2). This result
may indicate that the antidepressant potential of LuAA33810 is
most likely due to the activation of the MAPK/ERK and PI3K
signaling pathways. The similar effects of U0126 and
LY294002 pretreatment were found in the tail suspension test
(TST) in mice (Zeni et al. 2012). Those authors demonstrated
the involvement of MAPK/ERK and PI3K in the acute
antidepressant-like effect of ferulic acid, which is consistent
with our results showing the involvement of these signaling
pathways in the antidepressant activity of Lu AA33810. The
present data are also consistent with our previous findings and
results of other authors demonstrating that pretreatment with
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LY294002 prevented the antidepressant-like effect of com-
pounds in the FST in mice (Budni et al. 2012) and in the FST
in rats (Szewczyk et al. 2015).
In conclusion, our results demonstrate that the selective Y5
receptor antagonist, Lu AA33810, produces a rapid
antidepressant-like effect which might be mediated by the
BDNF as well as by MAPK/ERK and PI3K signaling path-
ways. We suppose that Y5 receptors may be an attractive
target for development of a novel antidepressant therapeutic
strategy; however, more data are needed in order to confirm
their importance in the treatment of depression (Table 1).
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